a16z raises $9B across three funds: a $1.5B Bio fund, a $5B Growth fund, and a $2.5B Venture fund
I am excited to announce that Andreessen Horowitz just raised a fresh $9B to invest via our Venture, Growth, and Bio Funds. We are grateful to our Limited Partners who have believed in us …
Context & Ripple Effects
This raise extends the escalation in a16z's fund sizing: the firm closed two funds totaling $4.5B in late 2020, bringing assets under management to $16.5B, and fourteen months later is pulling in $9B in one announcement — double that prior pair across three vehicles spanning seed-to-growth plus a dedicated Bio fund.
The Growth fund's $5B is the largest slice, signaling where the firm expects its capital to concentrate, while the standalone $1.5B Bio vehicle formalizes life sciences as a permanent franchise rather than a side bet. Four years on, the pattern holds: the firm's fifth growth fund alone reached $6.75B within a $15B+ multi-fund raise.
First-order effects
- Limited Partners committing to these funds are underwriting a16z's full-stage strategy at once — early, growth, and bio — concentrating more of their venture allocation with a single manager.
- Portfolio companies gain a deeper internal ladder: a16z can now fund a company from its Venture fund through a $5B Growth check without ceding the round to outside late-stage firms.
Second-order effects
- Rival multi-stage firms face pressure to match the scale, since founders choosing between term sheets increasingly weigh the size of the follow-on reserve behind each offer.
- A dedicated $1.5B Bio fund pushes generalist competitors to either build their own life-sciences vehicles or concede those deals to specialist managers.
Third-order effects
- If the trajectory from $4.5B to $9B to $15B+ per cycle continues, venture consolidates around a handful of mega-franchises whose brand and follow-on capacity set the terms for everyone else.
- Growth-stage capital of this size blurs the line between private and public investing, pushing later-stage valuations and exit expectations upward across the industry.
The trend: Venture fundraising is compounding into ever-larger multi-stage mega-funds, with a16z's cadence — $4.5B in 2020, $9B in 2022, $15B+ by 2026 — marking the pace.